High risk of in-breast tumor recurrence after BRCA1/2-associated breast cancer

Breast Cancer Research and Treatment

Volumn 147, Issue 3, 2014, Pages 571-578

  Nilsson, Martin P ^a   Hartman, Linda ^b   Kristoffersson, Ulf ^b   Johannsson, Oskar T ^c   Borg, Åke ^b   Henriksson, Karin ^d   Lanke, Elsa ^b   Olsson, Håkan ^a   Loman, Niklas ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^d South Swedish Regional   (Sweden)

Author keywords

BRCA1 2; Breast conserving therapy; Hereditary breast cancer; Local recurrence; Mastectomy; Radiotherapy

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; BRCA1 PROTEIN, HUMAN; BRCA2 PROTEIN, HUMAN;

ADULT; AGE; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SCREENING; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PRIMARY TUMOR; TUMOR INVASION; TUMOR SUPPRESSOR GENE; BREAST NEOPLASMS; COMPARATIVE STUDY; GENETICS; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; SEGMENTAL MASTECTOMY; SURVIVAL RATE; SWEDEN;

ADULT; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; HETEROZYGOTE; HUMANS; MASTECTOMY; MASTECTOMY, SEGMENTAL; MIDDLE AGED; MUTATION; SURVIVAL RATE; SWEDEN;

EID: 84918548920     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-3115-3     Document Type: Article

References (25)

1. Tung N (2011) Management of women with BRCA mutations: a 41-year-old woman with a BRCA mutation and a recent history of breast cancer. JAMA, J Am Med Assoc 305(21):2211–2220. doi:10.1001/jama.2011.678
2. Lynch HT, Snyder C, Casey MJ (2013) Hereditary ovarian and breast cancer: what have we learned? Annals of oncology 24(Suppl 8):viii83–viii95. doi:10.1093/annonc/mdt313
3. Bordeleau L, Panchal S, Goodwin P (2010) Prognosis of BRCA-associated breast cancer: a summary of evidence. Breast Cancer Res Treat 119(1):13–24. doi:10.1007/s10549-009-0566-z
4. Croshaw RL, Marshall ML, Williams TL, Erb KM, Julian TB (2011) Prophylactic and Therapeutic Breast Conservation in BRCA1/2 mutation carriers. Int J Breast cancer 2011:481563. doi:10.4061/2011/481563
5. Evans DG, Ingham SL, Baildam A, Ross GL, Lalloo F, Buchan I, Howell A (2013) Contralateral mastectomy improves survival in women with BRCA1/2-associated breast cancer. Breast Cancer Res Treat 140(1):135–142. doi:10.1007/s10549-013-2583-1
6. Rhiem K, Engel C, Graeser M, Zachariae S, Kast K, Kiechle M, Ditsch N, Janni W, Mundhenke C, Golatta M, Varga D, Preisler-Adams S, Heinrich T, Bick U, Gadzicki D, Briest S, Meindl A, Schmutzler RK (2012) The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study. BCR: Breast Cancer Res 14(6):R156. doi:10.1186/bcr3369
7. Brekelmans CT, Tilanus-Linthorst MM, Seynaeve C, vd Ouweland A, Menke-Pluymers MB, Bartels CC, Kriege M, van Geel AN, Burger CW, Eggermont AM, Meijers-Heijboer H, Klijn JG (2007) Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases. Eur J Cancer 43(5):867–876. doi:10.1016/j.ejca.2006.12.009 Oxford, England: 1990
8. Garcia-Etienne CA, Barile M, Gentilini OD, Botteri E, Rotmensz N, Sagona A, Farante G, Galimberti V, Luini A, Veronesi P, Bonanni B (2009) Breast-conserving surgery in BRCA1/2 mutation carriers: are we approaching an answer? Ann Surg Oncol 16(12):3380–3387. doi:10.1245/s10434-009-0638-7
9. Haffty BG, Harrold E, Khan AJ, Pathare P, Smith TE, Turner BC, Glazer PM, Ward B, Carter D, Matloff E, Bale AE, Alvarez-Franco M (2002) Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. Lancet 359(9316):1471–1477. doi:10.1016/s0140-6736(02)08434-9
10. Kirova YM, Savignoni A, Sigal-Zafrani B, de La Rochefordiere A, Salmon RJ, This P, Asselain B, Stoppa-Lyonnet D, Fourquet A (2010) Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature. Breast Cancer Res Treat 120(1):119–126. doi:10.1007/s10549-009-0685-6
11. Metcalfe K, Lynch HT, Ghadirian P, Tung N, Kim-Sing C, Olopade OI, Domchek S, Eisen A, Foulkes WD, Rosen B, Vesprini D, Sun P, Narod SA (2011) Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat 127(1):287–296. doi:10.1007/s10549-010-1336-7
12. Pierce LJ, Levin AM, Rebbeck TR, Ben-David MA, Friedman E, Solin LJ, Harris EE, Gaffney DK, Haffty BG, Dawson LA, Narod SA, Olivotto IA, Eisen A, Whelan TJ, Olopade OI, Isaacs C, Merajver SD, Wong JS, Garber JE, Weber BL (2006) Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol 24(16):2437–2443. doi:10.1200/jco.2005.02.7888
13. Pierce LJ, Phillips KA, Griffith KA, Buys S, Gaffney DK, Moran MS, Haffty BG, Ben-David M, Kaufman B, Garber JE, Merajver SD, Balmana J, Meirovitz A, Domchek SM (2010) Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy. Breast Cancer Res Treat 121(2):389–398. doi:10.1007/s10549-010-0894-z
14. Robson ME, Chappuis PO, Satagopan J, Wong N, Boyd J, Goffin JR, Hudis C, Roberge D, Norton L, Begin LR, Offit K, Foulkes WD (2004) A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. BCR: Breast Cancer Res 6(1):R8–R17. doi:10.1186/bcr658
15. Robson M, Levin D, Federici M, Satagopan J, Bogolminy F, Heerdt A, Borgen P, McCormick B, Hudis C, Norton L, Boyd J, Offit K (1999) Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations. J Natl Cancer Inst 91(24):2112–2117
16. Seynaeve C, Verhoog LC, van de Bosch LM, van Geel AN, Menke-Pluymers M, Meijers-Heijboer EJ, van den Ouweland AM, Wagner A, Creutzberg CL, Niermeijer MF, Klijn JG, Brekelmans CT (2004) Ipsilateral breast tumour recurrence in hereditary breast cancer following breast-conserving therapy. Eur J Cancer 40(8):1150–1158. doi:10.1016/j.ejca.2004.01.017 Oxford, England: 1990
17. Valachis A, Nearchou AD, Lind P (2014) Surgical management of breast cancer in BRCA-mutation carriers: a systematic review and meta-analysis. Breast Cancer Res Treat. doi:10.1007/s10549-014-2890-1
18. Brandberg Y, Sandelin K, Erikson S, Jurell G, Liljegren A, Lindblom A, Linden A, von Wachenfeldt A, Wickman M, Arver B (2008) Psychological reactions, quality of life, and body image after bilateral prophylactic mastectomy in women at high risk for breast cancer: a prospective 1-year follow-up study. J Clin Oncol 26(24):3943–3949. doi:10.1200/jco.2007.13.9568
19. Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, Jeong JH, Wolmark N (2002) Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. New Engl J Med 347(16):1233–1241. doi:10.1056/NEJMoa022152
20. Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, Aguilar M, Marubini E (2002) Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. New Engl J Med 347(16):1227–1232. doi:10.1056/NEJMoa020989
21. Mavaddat N, Peock S, Frost D, Ellis S, Platte R, Fineberg E, Evans DG, Izatt L, Eeles RA, Adlard J, Davidson R, Eccles D, Cole T, Cook J, Brewer C, Tischkowitz M, Douglas F, Hodgson S, Walker L, Porteous ME, Morrison PJ, Side LE, Kennedy MJ, Houghton C, Donaldson A, Rogers MT, Dorkins H, Miedzybrodzka Z, Gregory H, Eason J, Barwell J, McCann E, Murray A, Antoniou AC, Easton DF (2013) Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst 105(11):812–822. doi:10.1093/jnci/djt095
22. Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, Godwin J, Gray R, Hicks C, James S, MacKinnon E, McGale P, McHugh T, Peto R, Taylor C, Wang Y (2005) Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366(9503):2087–2106. doi:10.1016/s0140-6736(05)67887-7
23. McGuire KP, Santillan AA, Kaur P, Meade T, Parbhoo J, Mathias M, Shamehdi C, Davis M, Ramos D, Cox CE (2009) Are mastectomies on the rise? A 13-year trend analysis of the selection of mastectomy versus breast conservation therapy in 5865 patients. Ann Surg Oncol 16(10):2682–2690. doi:10.1245/s10434-009-0635-x
24. Heemskerk-Gerritsen BA, Menke-Pluijmers MB, Jager A, Tilanus-Linthorst MM, Koppert LB, Obdeijn IM, van Deurzen CH, Collee JM, Seynaeve C, Hooning MJ (2013) Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy BRCA1 and BRCA2 mutation carriers: a prospective analysis. Ann Oncol 24(8):2029–2035. doi:10.1093/annonc/mdt134
25. Metcalfe K, Gershman S, Ghadirian P, Lynch HT, Snyder C, Tung N, Kim-Sing C, Eisen A, Foulkes WD, Rosen B, Sun P, Narod SA (2014) Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. BMJ (Clin Res Ed) 348:g226. doi:10.1136/bmj.g226